Antiangiogenic therapy and surgical practice.

Research output: Contribution to journalArticle

Standard

Antiangiogenic therapy and surgical practice. / John, AR; Bramhall, Simon; Eggo, Margaret.

In: British Journal of Surgery, Vol. 95, No. 3, 01.03.2008, p. 281-93.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{6d45b4aa807d42549ddd89f62f2e3356,
title = "Antiangiogenic therapy and surgical practice.",
abstract = "BACKGROUND: Antiangiogenic therapy has become a reality with the recent introduction of bevacizumab, a monoclonal antibody against vascular endothelial growth factor. METHODS: Relevant medical literature from PubMed, National Institute for Health and Clinical Excellence and National Institutes of Health websites to August 2007 was reviewed. RESULTS AND CONCLUSIONS: Although often described as the fourth modality of treatment after surgery, radiotherapy and chemotherapy, many antiangiogenic drugs have failed to live up to expectations. Nevertheless, research continues and there are reasons to believe that antiangiogenic therapy may yet have a future in the clinical setting.",
author = "AR John and Simon Bramhall and Margaret Eggo",
year = "2008",
month = mar,
day = "1",
doi = "10.1002/bjs.6108",
language = "English",
volume = "95",
pages = "281--93",
journal = "British Journal of Surgery",
issn = "0007-1323",
publisher = "Wiley",
number = "3",

}

RIS

TY - JOUR

T1 - Antiangiogenic therapy and surgical practice.

AU - John, AR

AU - Bramhall, Simon

AU - Eggo, Margaret

PY - 2008/3/1

Y1 - 2008/3/1

N2 - BACKGROUND: Antiangiogenic therapy has become a reality with the recent introduction of bevacizumab, a monoclonal antibody against vascular endothelial growth factor. METHODS: Relevant medical literature from PubMed, National Institute for Health and Clinical Excellence and National Institutes of Health websites to August 2007 was reviewed. RESULTS AND CONCLUSIONS: Although often described as the fourth modality of treatment after surgery, radiotherapy and chemotherapy, many antiangiogenic drugs have failed to live up to expectations. Nevertheless, research continues and there are reasons to believe that antiangiogenic therapy may yet have a future in the clinical setting.

AB - BACKGROUND: Antiangiogenic therapy has become a reality with the recent introduction of bevacizumab, a monoclonal antibody against vascular endothelial growth factor. METHODS: Relevant medical literature from PubMed, National Institute for Health and Clinical Excellence and National Institutes of Health websites to August 2007 was reviewed. RESULTS AND CONCLUSIONS: Although often described as the fourth modality of treatment after surgery, radiotherapy and chemotherapy, many antiangiogenic drugs have failed to live up to expectations. Nevertheless, research continues and there are reasons to believe that antiangiogenic therapy may yet have a future in the clinical setting.

U2 - 10.1002/bjs.6108

DO - 10.1002/bjs.6108

M3 - Article

C2 - 18278790

VL - 95

SP - 281

EP - 293

JO - British Journal of Surgery

JF - British Journal of Surgery

SN - 0007-1323

IS - 3

ER -